Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient’s eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon’s fibroblast (HTF) lea...
| Main Author: | |
|---|---|
| Format: | Book Section |
| Language: | English |
| Published: |
Institute of Graduate Studies, UiTM
2018
|
| Subjects: | |
| Online Access: | https://ir.uitm.edu.my/id/eprint/20553/ |
| _version_ | 1848805042364088320 |
|---|---|
| author | Md Noh, Siti Munirah |
| author_facet | Md Noh, Siti Munirah |
| author_sort | Md Noh, Siti Munirah |
| building | UiTM Institutional Repository |
| collection | Online Access |
| description | Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient’s eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon’s fibroblast (HTF) leads to significant cases of surgical failure. Anti-vascular endothelial growth factor (VEGF) has become the focus in current scar modulation strategy. Improved bleb morphology following trabeculectomy augmented with ranibizumab has been reported. However, mechanism of actions of ranibizumab on HTF is not well understood. Therefore, this in vitro study was conducted to elucidate mechanism of actions of ranibizumab on HTF. HTF used in this study were propagated from Tenon’s capsule obtained from patients undergoing trabeculectomy. Firstly, isolated and characterized HTF were treated with different concentrations of ranibizumab in serum and serum-free media for 24 and 48 hours and then HTF viability was measured using MTT assay. Then, HTF were extracted to measure the expression of collagen Type 1 (COL1A1), fibronectin (FN), transforming growth factor-β1 and -β2 (TGF-β1 &TGF-β2) using qRT-PCR and ELISA. The experiment was followed with metabolomics profiling which was performed to identify the most significant metabolite regulated by ranibizumab… |
| first_indexed | 2025-11-14T22:04:44Z |
| format | Book Section |
| id | uitm-20553 |
| institution | Universiti Teknologi MARA |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T22:04:44Z |
| publishDate | 2018 |
| publisher | Institute of Graduate Studies, UiTM |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | uitm-205532018-07-06T05:58:56Z https://ir.uitm.edu.my/id/eprint/20553/ Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh Md Noh, Siti Munirah RC Internal Medicine RM Therapeutics. Pharmacology Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient’s eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon’s fibroblast (HTF) leads to significant cases of surgical failure. Anti-vascular endothelial growth factor (VEGF) has become the focus in current scar modulation strategy. Improved bleb morphology following trabeculectomy augmented with ranibizumab has been reported. However, mechanism of actions of ranibizumab on HTF is not well understood. Therefore, this in vitro study was conducted to elucidate mechanism of actions of ranibizumab on HTF. HTF used in this study were propagated from Tenon’s capsule obtained from patients undergoing trabeculectomy. Firstly, isolated and characterized HTF were treated with different concentrations of ranibizumab in serum and serum-free media for 24 and 48 hours and then HTF viability was measured using MTT assay. Then, HTF were extracted to measure the expression of collagen Type 1 (COL1A1), fibronectin (FN), transforming growth factor-β1 and -β2 (TGF-β1 &TGF-β2) using qRT-PCR and ELISA. The experiment was followed with metabolomics profiling which was performed to identify the most significant metabolite regulated by ranibizumab… Institute of Graduate Studies, UiTM 2018 Book Section PeerReviewed text en https://ir.uitm.edu.my/id/eprint/20553/1/ABS_SITI%20MUNIRAH%20MD%20NOH%20TDRA%20VOL%2013%20IGS%2018.pdf Md Noh, Siti Munirah (2018) Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh. (2018) In: The Doctoral Research Abstracts. IGS Biannual Publication, 18 (18). Institute of Graduate Studies, UiTM, Shah Alam. |
| spellingShingle | RC Internal Medicine RM Therapeutics. Pharmacology Md Noh, Siti Munirah Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh |
| title | Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh |
| title_full | Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh |
| title_fullStr | Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh |
| title_full_unstemmed | Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh |
| title_short | Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh |
| title_sort | mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / siti munirah md noh |
| topic | RC Internal Medicine RM Therapeutics. Pharmacology |
| url | https://ir.uitm.edu.my/id/eprint/20553/ |